Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION
Hofseth BioCare ASA (HBC) · publisert 2023-02-15 17:12 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass | Tolket via |
|---|---|---|---|---|---|---|---|---|
| Hofseth International AS nærstående | Close associate of board member, Roger Hofseth | acquisition | 93 434,4 | 24 000 NOK | 2022-05-11 | – | Oslo Stock Exchange, main list | rules · til gjennomgang |
| Hofseth International AS nærstående | Close associate of board member, Roger Hofseth | acquisition | 150 429,44 | 53 572 NOK | 2022-12-29 | – | Oslo Stock Exchange, main list | rules · til gjennomgang |
| Hofseth International AS nærstående | Close associate of board member, Roger Hofseth | acquisition | 599 530,72 | 178 215 NOK | 2022-12-30 | – | Oslo Stock Exchange, main list | rules · til gjennomgang |
Vedlegg
- PDMR notification form - Hofseth International AS 11 May 2022.pdf (tekst hentet ut)
- PDMR notification form - Hofseth International AS 29 December 2022.pdf (tekst hentet ut)
- PDMR notification form - Hofseth International AS 30 December 2022.pdf (tekst hentet ut)
Meldingstekst
Hofseth International AS ("HI"), a close associate of Hofseth Biocare ASA's (the
"Company") board member Roger Hofseth, has notified the Company that HI has made
the following purchases of shares in the Company.
On 11 May 2022, HI purchased 24,000 shares in the Company at an average price of
approximately NOK 3,89 for a total subscription amount of NOK 93,434.4.
On 29 December 2022, HI purchased 53,572 shares in the Company at an average
price of approximately NOK 2,80 for a total subscription amount of NOK
150,429.44.
On 30 December 2022, HI purchased 178,215 shares in the Company at an average
price of approximately NOK 3,36 for a total subscription amount of NOK
599,530.72.
Please see the attached notification forms for further information.
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no
This information is subject to the disclosure requirements in the Market Abuse
Regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading
Act section 5-12.